+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of enpatoran in adults aged 18 to 75 with active cutaneous manifestations of lupus erythematosus, either with or without systemic disease. This global, multicenter Phase 3 study aims to understand how enpatoran works compared to a placebo in addition to standard care over a 24-week treatment period. The study is sponsored by EMD Serono Research & Development Institute, Inc. and includes participants diagnosed with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, andor Acute Cutaneous Lupus Erythematosus, with or without systemic lupus erythematosus. Participants are randomly assigned to receive either enpatoran tablets or matching placebo tablets taken orally twice daily for 24 weeks while continuing their standard of care treatments. The study intervention is administered as film-coated tablets, and participants are monitored throughout the treatment period. Visits occur every four weeks, with a televisit at Week 2, allowing ongoing assessment of the participants condition and response to treatment. Throughout the study, participants undergo regular evaluations including the Cutaneous Lupus Erythematosus Disease Area and Severity Index CLASI and other measures of lupus activity and symptom changes. Researchers monitor for treatment-emergent adverse events, serious adverse events, and laboratory abnormalities from Day 1 to Week 24. The primary outcome is the percentage of participants achieving a 70% or greater reduction in CLASI-A score at Week 24. Total study participation can last up to 35 weeks, including screening and follow-up assessments.

Age: 18Years - 75YearsAll GendersPhase 3
70 locations
E

Actively Recruiting

Researchers are evaluating ELV001 as an add-on therapy for adults with active rheumatoid arthritis who have not responded adequately to methotrexate and tumor necrosis factor inhibitors. This Phase 2 randomized, double-blind, placebo-controlled study aims to assess the safety and effectiveness of different doses of ELV001. Approximately 180 to 220 participants aged 18 to 75 years will be enrolled. Participants will be assigned to one of four groups placebo, ELV001 25 mg, 75 mg, or 125 mg daily. The study includes a 4-week screening period, a 12-week double-blind placebo-controlled treatment phase, followed by a 12-week extension where some participants receive higher doses of ELV001. A 4-week safety follow-up concludes the 32-week study. During the study, participants will undergo regular assessments including disease activity scoring, joint counts, blood tests, vital signs, electrocardiograms, and questionnaires about health and function. Researchers will monitor adverse events and drug levels in the blood. The main outcome measured is the change in disease activity score from baseline to week 12. Safety and efficacy will be tracked through week 28, with total participation lasting up to 32 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
34 locations
E

Actively Recruiting

Researchers are evaluating the medicine BI 3000202 in adults with moderate to severe systemic lupus erythematosus SLE to find out if it helps manage the condition. This phase II study randomly assigns participants to one of five groups, including four different doses of BI 3000202 and one placebo group. The goal is to determine the best dose while monitoring the safety and effects of the medicine. Participants take their assigned tablets daily for one year while continuing their regular SLE treatments. The study involves a randomized, placebo-controlled, double-blind design with parallel groups. Four groups receive varying doses of BI 3000202, and one group receives placebo tablets that look the same but contain no medicine. During the study, participants visit the study site regularly for health checks, monitoring of any side effects, and assessments of their disease activity using tools like the Systemic Lupus Erythematosus Responder Index. The study lasts a bit longer than one year, allowing thorough evaluation of treatment effects and safety. Researchers compare results among the groups to understand the medicines impact on SLE.

Age: 18Years - 74YearsAll GendersPhase 2
139 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new short 6-week daily rifapentine treatment compared to the standard 12-16 week rifamycin-based treatments for latent Mycobacterium tuberculosis infection LTBI. This trial focuses on people at higher risk of developing active tuberculosis TB and is conducted in locations with varying TB rates where LTBI treatment is routinely provided. The study aims to determine if the shorter treatment is not less safe or effective than the longer standard treatments. Participants are randomly assigned to one of two treatment groups the experimental group receives 600 mg of rifapentine daily for 6 weeks, while the control group receives one of three standard regimens lasting 12 to 16 weeks, including combinations of rifapentine, isoniazid, and rifampin. Dose adjustments are made based on patient weight following established guidelines. Treatments are given according to random assignment and participants are followed for 24 months to assess outcomes. During the study, researchers monitor treatment completion rates, adverse drug reactions, and new cases of active tuberculosis. Safety assessments include tracking serious side effects and drug discontinuation rates. Effectiveness is measured by the occurrence of culture-confirmed or clinical TB within 24 months of enrollment. The study involves regular evaluations and follow-up visits over two years to collect data on treatment tolerability, safety, and TB prevention outcomes.

All AgesAll GendersPhase 2Phase 3
21 locations
S

Actively Recruiting

Researchers are studying the use of different antibiotic treatments for newborns with all-risk asymptomatic congenital syphilis, a condition passed from mother to baby during pregnancy. This phase II study aims to evaluate the safety and how the body processes these antibiotics in newborns, comparing three different treatment options. The treatments being evaluated include a 10-day course of oral Linezolid given twice daily, a 10-day course of oral Amoxicillin given twice daily, and a single intramuscular injection of Benzathine Penicillin G. Participants are randomly assigned to one of these three treatment groups to compare their effects. During the study, newborns will be closely monitored from enrollment through 10 days of treatment, with assessments including blood and cerebrospinal fluid antibiotic levels and tracking any adverse events up to 24 weeks. Researchers will also evaluate clinical outcomes over this period. The total participation may last up to 24 weeks to ensure safety and effectiveness monitoring.

Age: 0Days - 7DaysAll GendersPhase 2
3 locations
O

Actively Recruiting

This trial focuses on participants with autoimmune and inflammatory conditions who have previously taken part in a Novartis study involving secukinumab. It aims to evaluate the long-term safety of secukinumab in those who continue to benefit from the treatment but cannot access the marketed version. The study is a Phase 4, open-label extension designed to provide ongoing assessment of this medication. Participants will receive secukinumab injections under the skin at doses of 75 mg, 150 mg, or 300 mg every four weeks, depending on their previous treatment dose in the parent trial. Pediatric dosing will be limited according to weight categories and prior evaluated maximum doses. Investigators can adjust doses based on clinical needs and health authority guidance. This study involves a single group receiving secukinumab with no placebo or comparator. During the study, participants will be monitored for up to two years to assess the occurrence of any adverse or serious adverse events. The trial will involve regular evaluations to track the participants safety while continuing secukinumab treatment. The total duration for participation can extend until the study ends in 2030, with ongoing safety assessments throughout this period.

Age: 6Years - 100YearsAll GendersPhase 4
171 locations